[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

Roche reported strong Q3 2026 performance with sales growth of +7% at constant exchange rates and +8% in CHF. The Pharmaceuticals Division grew +7% at CER driven by key medicines including Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo. The Diagnostics Division grew +4% at CER. The company confirmed its full-year 2026 outlook expecting mid single-digit sales growth and high single-digit core earnings per share growth at CER.